We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-4.03%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$22M
Cap. Flow
+$67.7M
Cap. Flow %
22.04%
Top 10 Hldgs %
56.38%
Holding
71
New
21
Increased
13
Reduced
13
Closed
22

Top Buys

Rank Stock Value
1
TAK icon
Takeda Pharmaceutical
TAK
+$15.3M
2
LH icon
Labcorp
LH
+$14.9M
3
CTLT
CATALENT, INC.
CTLT
+$13.9M
4
LLY icon
Eli Lilly
LLY
+$12.1M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.5M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$15.6M
2
AVTR icon
Avantor
AVTR
+$10M
3
HOLX
Hologic
HOLX
+$8.85M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$5.82M
5
CNC icon
Centene
CNC
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.14%
2 Miscellaneous 18.73%
3 Real Estate 4.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
1
Labcorp
LH
$26.3B
$19.9M 6.49%
113,193
+72,781
+180% +$14.9M
HUM icon
2
Humana
HUM
$46.2B
$15.9M 5.17%
32,729
+5,623
+21% +$2.74M
TAK icon
3
Takeda Pharmaceutical
TAK
$59.5B
$14.3M 4.66%
+1,102,280
New +$15.3M
BAX icon
4
Baxter International
BAX
$12.2B
$13.2M 4.3%
245,093
+155,230
+173% +$9.34M
QGEN icon
5
Qiagen
QGEN
$8.86B
$12.5M 4.09%
286,621
-88,924
-24% -$4.39M
LLY icon
6
Eli Lilly
LLY
$1.01T
$12.4M 4.03%
+38,311
New +$12.1M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.5B
$12.3M 4.01%
145,374
+119,399
+460% +$10.6M
ICLR icon
8
Icon
ICLR
$13.4B
$12.2M 3.98%
66,437
+16,719
+34% +$3.64M
BMY icon
9
Bristol-Myers Squibb
BMY
$130B
$11.3M 3.67%
+158,721
New +$11.5M
CTLT
10
DELISTED
CATALENT, INC.
CTLT
$10.1M 3.3%
+140,077
New +$13.9M
CI icon
11
Cigna
CI
$74.1B
$9.46M 3.08%
34,099
-6,273
-16% -$1.77M
OHI icon
12
Omega Healthcare
OHI
$14.2B
$9.25M 3.01%
+313,762
New +$9.84M
ELUT icon
13
Elutia
ELUT
$35.9M
$8.21M 2.67%
1,139,932
+6,749
+0.6% +$45.1K
BDX icon
14
Becton Dickinson
BDX
$49.5B
$7.64M 2.49%
+34,282
New +$8.53M
ELV icon
15
Elevance Health
ELV
$89.5B
$7.45M 2.43%
+16,402
New +$7.85M
ZTS icon
16
Zoetis
ZTS
$30.2B
$6.57M 2.14%
44,286
+3,186
+8% +$532K
RNAC icon
17
Cartesian Therapeutics
RNAC
$239M
$6.46M 2.1%
131,280
-22,441
-15% -$1.23M
AZN icon
18
AstraZeneca
AZN
$253B
$5.54M 1.8%
+50,524
New +$6.41M
MCK icon
19
McKesson
MCK
$103B
$5.5M 1.79%
16,168
+184
+1% +$63.9K
OCUL icon
20
Ocular Therapeutix
OCUL
$2.17B
$4.42M 1.44%
1,064,295
+304,067
+40% +$1.53M
EHC icon
21
Encompass Health
EHC
$12.2B
$3.75M 1.22%
+82,929
New +$4.15M
THC icon
22
Tenet Healthcare
THC
$21.4B
$3.64M 1.18%
70,535
+23,093
+49% +$1.37M
VTR icon
23
Ventas
VTR
$45.2B
$3.44M 1.12%
+85,683
New +$4.21M
ALBO
24
DELISTED
Albireo Pharma Inc
ALBO
$3.34M 1.09%
172,621
+134,786
+356% +$2.79M
BIO icon
25
Bio-Rad Laboratories Class A
BIO
$10.1B
$2.91M 0.95%
6,984
-9,044
-56% -$4.51M
1
2 3

Similar funds

UVM
Upfront Ventures Management Santa Monica, California $12.3M AUM
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Endurant Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Endurant Capital Management held 71 positions worth $307M, up 7.7% from $285M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Endurant Capital Management deployed $67.7M of net new capital in Q3 2022, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 70% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Avantor, an estimated $10M trimmed.

  • Endurant Capital Management's largest Q3 2022 buy was Takeda Pharmaceutical: 1,102,280 shares worth $14.3M.
  • Endurant Capital Management added most to Labcorp in Q3 2022, an estimated $14.9M increase.
  • Endurant Capital Management's biggest Q3 2022 reduction was Avantor, cutting an estimated $10M.
  • Endurant Capital Management fully exited Boston Scientific in Q3 2022, selling an estimated $15.6M.
  • Endurant Capital Management's ten largest holdings make up 56% of its $307M portfolio in Q3 2022.
  • Endurant Capital Management opened 21 new positions and closed 22 in Q3 2022.
  • Endurant Capital Management's portfolio value rose 7.7% quarter-over-quarter to $307M.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.